BIOLASE Granted Canadian License to Sell Its Flagship EPIC 10 Soft-Tissue Diode Laser

BIOLASE Granted Canadian License to Sell Its Flagship EPIC 10 Soft-Tissue Diode 
IRVINE, CA -- (Marketwired) -- 12/30/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, and a pioneer in laser surgery in other medical specialties,
today announced that it has received a license from the Health
Canada-Medical Device Bureau to sell its EPIC dental soft-tissue
diode laser systems throughout Canada. BIOLASE sells its products in
Canada through a direct sales force and select distributors. 
Chairman and CEO Federico Pignatelli commented, "With an estimated
19,000 dentists, Canada has historically represented one of BIOLASE's
most robust markets for its high-tech laser products. We believe that
there is pent-up demand for the EPIC soft-tissue diode laser in
Canada from our large and loyal installed base, and this approval is
an important milestone for BIOLASE. We expect the Canadian market to
be a strong contributor to our growth in 2014 with the ability to
sell our newly cleared flagship EPIC 10-watt soft-tissue diode laser
in addition to our revolutionary WaterLase iPlus." 
Tannis Sigurdson, Canada Sales Manager commented, "We are excited to
have received Health Canada approval for our Epic 10 soft tissue
laser. A large group of dentists and hygienists have been waiting
very patiently for this approval of our newest generation of our
Laser Family, and we are thrilled to add EPIC 10 to our Canadian
product portfolio. 
"Biolase lasers are highly regarded as state of the art systems that
create superior surgical and aesthetic results within a dental
practice. The Epic 10's new sleek and versatile design will just make
it easier for dentists to integrate it in their practice, and the
added whitening feature will offer their patients quick and easy
laser bleaching in one visit. We do believe that dental lasers will
be the standard of care in every dental practice." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners and
in-office milling machines; products that are focused on technologies
that advance the practice of dentistry and medicine. The Company's
proprietary laser products incorporate approximately 300 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its innovative products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are revolutionary dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental
imaging equipment. BIOLASE has sold more than 24,000 lasers. Other
laser products under development address ophthalmology and other
medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Google+ at, Instagram at and YouTube at  
BIOLASE(R), WaterLase(R), and EPIC(TM) are registered trademarks or
trademarks of BIOLASE, Inc. 
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
 Statements contained in this press release that refer to
BIOLASE's estimated or anticipated future results or other
non-historical facts are forward-looking statements, as are any
statements in this press release concerning prospects related to
BIOLASE's strategic initiatives, product introductions and
anticipated financial performance. Forward-looking statements can
also be identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
"may," "will," and variations of these words or similar expressions.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect BIOLASE's current
perspective of existing trends and information and speak only as of
the date of this release. Actual results may differ materially from
BIOLASE's current expectations depending upon a number of factors
affecting BIOLASE's business. These factors include, among others,
adverse changes in general economic and market conditions,
competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of
new product offerings and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein.  
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
Press spacebar to pause and continue. Press esc to stop.